Avalon GloboCare (NASDAQ:ALBT) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Avalon GloboCare (NASDAQ:ALBT) to a strong sell rating in a report issued on Saturday.

Avalon GloboCare Stock Down 7.1%

Shares of Avalon GloboCare stock opened at $2.60 on Friday. Avalon GloboCare has a 12-month low of $1.87 and a 12-month high of $11.66. The company has a market capitalization of $9.98 million, a price-to-earnings ratio of -0.13 and a beta of 0.02. The firm’s 50-day moving average price is $2.31 and its two-hundred day moving average price is $3.52.

Avalon GloboCare (NASDAQ:ALBT) last issued its earnings results on Thursday, August 14th. The company reported ($2.02) EPS for the quarter. The firm had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.